Sugi Predict

Sugi Predict / Compounds / SCHEMBL1415779

SCHEMBL1415779

SCHEMBL1415779

C=CCc1nc2ccccc2c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.58
▸ GPR3 P46089 2/20 0.44
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ MAOA P21397 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GLA P06280 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ NQO2 P16083 1/20 0.38
▸ DRD1 P21728 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ SLC6A2 P23975 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28754732 0.80 KDM4E (0.38) KMT2AKDM4EALDH1A1RAB9AMAOA
SCHEMBL17867154 0.80 KMT2A (0.41) KMT2AKDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL5461996 0.80 ACHE (0.52) KMT2AKDM4EALDH1A1RAB9AMAOA
SCHEMBL15882934 0.80 KDM4E (0.37) KMT2AKDM4EALDH1A1RAB9AMAOA
SCHEMBL5806670 0.78 KMT2A (0.64) KMT2AGPR3KDM4EALDH1A1RAB9A
SCHEMBL12485862 0.76 ERN1 (0.42) KMT2AGPR3KDM4EALDH1A1SMN1; SMN2
SCHEMBL8318642 0.76 KDM4E (0.50) KMT2AKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL9273537 0.76 KDM4E (0.52) KMT2AKDM4EALDH1A1RAB9AMAOA
SCHEMBL29099851 0.75 KMT2A (0.51) KMT2AGPR3KDM4EALDH1A1RAB9A
SCHEMBL15522442 0.74 KMT2A (0.64) KMT2AGPR3KDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969889-B Preparation method of phenanthridine or chiral phenanthridine compound 瑞博(杭州)医药科技有限公司 2024-03-26 — — CN claimed
CN-116969889-A Preparation method of phenanthridine or chiral phenanthridine compound 瑞博(杭州)医药科技有限公司 2023-10-31 — — CN claimed
CN-116969889-B Preparation method of phenanthridine or chiral phenanthridine compound 瑞博(杭州)医药科技有限公司 2024-03-26 — — CN disclosed
CN-116969889-A Preparation method of phenanthridine or chiral phenanthridine compound 瑞博(杭州)医药科技有限公司 2023-10-31 — — CN disclosed
CN-116730916-A Method for synthesizing 6-methylphenidate compound by photocatalysis 安徽理工大学 2023-09-12 — — CN disclosed
US-9962377-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2018-05-08 — — US disclosed
US-20160279120-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS TAKEDA GMBH (DE) 2016-09-29 — — US disclosed
US-9387205-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2016-07-12 — — US disclosed
US-20150352096-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-10 — — US disclosed
US-9149479-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors TAKEDA GMBH (DE) 2015-10-06 — — US disclosed
US-20150119389-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-30 — — US disclosed
WO-2005087744-A1 NOVEL THIO-CONTAINING HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 — — WO disclosed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 — — WO disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 — — WO disclosed
WO-2005084104-A2 NOVEL ISOAMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 — — WO disclosed
WO-2005085225-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 — — WO disclosed
WO-2005077906-A1 NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENENTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS ALTANA PHARMA AG (DE) 2005-08-25 — — WO disclosed
EP-1000034-B1 SUBSTITUTED 6-ALKYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-09-18 — — EP disclosed
US-6214839-B1 TREATING AIRWAY DISORDERS, DERMATOSIS, RHEUMATIOD ARTHRITIS, AND CROHN'S DISEASE BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH 2001-04-10 — — US disclosed
US-6214839-B1 TREATING AIRWAY DISORDERS, DERMATOSIS, RHEUMATIOD ARTHRITIS, AND CROHN'S DISEASE BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH 2001-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352096-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE12 KMT2A 907/4885GPR3 380/4885KDM4E 237/4885
US-20150119389-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C KMT2A 1837/4885GPR3 668/4885KDM4E 347/4885
US-20160279120-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE12, PDE4B KMT2A 750/4885GPR3 475/4885KDM4E 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.